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Introduction 49
Dementia currently affects more than 34 million people worldwide, with estimations that more than 50 110 million people will be affected by dementia in 2050 (1) . Alzheimer"s disease (AD), the most 51 common form of dementia, causes enormous personal, social and financial burdens on the patients, 52 their caregivers and society. Current pharmacological treatments offer symptomatic benefits, thus 53 effective disease-modifying therapies are urgently needed. As AD is a neurodegenerative disease, 54 cell replacement strategies are a potential target for therapeutic intervention; such as promoting 55 endogenous neurogenesis. 56
Endogenous neurogenesis is evident in two areas of the brain: the hippocampal dentate gyrus (DG) 57 and the wall of the lateral ventricles (subventricular zone-SVZ) (2) (3) (4) (5) . In mammals, neural 58 progenitors at the base of the DG granular layer (subgranular layer, SGL) give rise to neurons that 59 can be functionally integrated in the granular cell layer, whereas the SVZ neural progenitors follow a 60 distinct pathway, the Rostral Migratory Stream (RMS), to the olfactory bulb (OB) where they create 61 interneurons. In the healthy adult brain, SVZ neurogenesis maintains cellular turnover in the OB, 62 contributing to olfactory adaptation and learning (6) (7) (8) , whereas in DG endogenous neurogenesis is 63 crucial for the hippocampal-dependent spatial learning and memory throughout life (8) (9) (10) (11) . 64
Groundbreaking work over the last two decades has demonstrated the presence of the same 65 neurogenic niches in the adult human brain, including the temporal horn of the lateral ventricles, 66 located adjacent to the hippocampal formation (12) (13) (14) (15) . Consequently, there has been evolving 67 interest in the therapeutic potential of strategies that aim to enhance endogenous neurogenesis. Many 68 available compounds, of which some are already in clinical use, such as retinoid agonists, 69 cannabinoids, Selective Serotonin Reuptake Inhibitors (SSRIs), cholinesterase inhibitors and certain 70 hormones have a substantial positive impact on neurogenesis in animals, by either stimulating 71 proliferation of endogenous neural stem cells and/or increasing their differentiation into neurons (for 72 reviews see 16 and 17) . 73 4 Ekonomou However, the potential clinical relevance for AD patients is less clear, with contradictory results 74 from the small number of human autopsy studies that have been undertaken. Ziabreva et al. (2006) 75 and Perry et al. (2012) identified an increase at the proliferation stages of neurogenesis in the anterior 76 SVZ (18) and the temporal horn SVZ and DG (19) respectively, but a reduction in the early stage 77 neural progenitors in the SVZ of AD patients compared to age-matched controls (18) . In a previous 78 study from our group foucssing on a different cohort of AD patients, including people with 79 concurrent cerebrovascular disease, no statistically significant difference was observed in early 80 neuronal marker immunoreactivity between AD and controls (19) . In contrast, in another study 81 increased numbers of neural progenitors were detected in the DG of AD patients, which resulted in 82 an unsuccessful maturation to newly-generated neurons (20) . In a report focusing on younger 83 patients with AD, increased glial proliferation was reported in the SGL, but no alteration in 84 neurogenesis was identified (21) . Other studies suggested that both concurrent cerebrovascular 85 pathology (22) (23) (24) (25) (26) and the severity of cortical cholinergic system deficits (18, 19, 27) are likely to 86 represent key mediating factors in either increasing or decreasing endogenous neurogenesis, 87 respectively. Hence, the influence of age-associated neuropathological changes on neurogenesis is 88 not fully elucidated, in particular with respect to the early stages of the AD process. 89
Similar to the often contradictory data from studies on human tissue, studies investigating 90 neurogenesis in transgenic animal models carrying the human mutations for APP and/or PS1 or PS2 91 and/or tau proteins reported increased, decreased or unchanged progenitor activity (28) (29) (30) (31) (32) . 92
To further elucidate the role of neurogenesis in AD, we examined post mortem brain tissue from a 93 subset of participants of the Medical Research Council Cognitive Function and Ageing Study (MRC 94 CFAS), including individuals who died with and without dementia, and who showed all 95 neuropathological stages of AD-associated tau pathology (i.e., Braak stages 0 to VI), without any 96 other neuropathology such as cerebrovascular disease. For the first time, the levels of astrocytic and 97 microglia cell numbers were also identified in the different Braak stages. Our study primarily aimed 98 5 Ekonomou to identify alterations in the various phases of endogenous neurogenesis in relation to dementia and 99 AD-associated pathology. 100 101
Methods and Materials 102
Tissue was obtained from brains donated to the UK MRC CFAS. Details of the study have been 103 described elsewhere (33, 34) and can also be found at the website (www.cfas.ac.uk). In brief, MRC 104 CFAS included an initial cohort of 13,004 individuals, representative of the population aged 65 and 105 over recruited from general practice lists in five areas of England and Wales. The cohort for the 106 current study consists of 28 brain samples selected from those participants of the MRC CFAS who 107 agreed to donate their brain on death and among whom a successful autopsy was performed. At the 108 time of sampling, 456 brain donations had been made to the study, 114 of which were available and 109 had sufficient tissue for the current analysis (those from the Cambridgeshire and Newcastle centres). 110
Those who received a neuropathological diagnosis of "normal brain", "possible AD", "probable AD" 111 or "definite AD" were considered for selection into the study. Those with any diagnosis of Lewy 112 body disease, cerebrovascular disease or other neuropathology were excluded. Neurofibrillary tangle 113 (NFT) pathology was assessed using Braak staging (35-37) after histochemistry, by experienced 114 neuropathologists working in the MRC CFAS study, blinded to clinical findings (supplementary 115 figure S1). Neurofibrillary Braak stages are stated based on the topographical distribution of 116 neurofibrillary tangles and neuropil threads which are neuropathological hallmark lesions of AD; at 117
Braak stages I and II, NFTs are confined mainly to the transentorhinal region of the brain; at stages 118 III and IV they are also found in limbic regions such as the hippocampus, and at the severe stages V 119 and VI they are extensively located in other brain areas, including the neocortex (35, 36) . The 120 neuropathological diagnosis of AD was done according to internationally accepted criteria that 121 include the assessment of amyloid-β pathology, which progresses spatially and temporally 122 differently than the tau pathology. Of note, similar to many other studies, we used Braak stages to 123 6 Ekonomou indicate the overall severity of AD pathology, but not to directly compare the severity of tau 124 pathology with neurogenesis; in this study neither tau nor amyloid-β pathology was directly 125 compared with neurogenesis in the same topographic locations. 126
Diagnosis of dementia 127
Dementia status at death was determined based on interviews during the last years of life, including 128 the full GMS-AGECAT diagnostic algorithm that was equivalent to that in the Diagnostic and 129
Statistical Manual of Mental Disorders, third edition, revised (DSM-III-R), interviews with 130 informants after the respondent's death when this was possible and death certification (37) . Of the 28 131 individuals included in the present study, 13 received a study diagnosis of dementia at death. 132
Demographic data are shown in table 1. 133 Immunohistochemistry 134 8m thick, paraffin-embedded sections were obtained at the level of basal ganglia, including the 135 anterior SVZ, and also at the level of hippocampus, including the temporal horn of the SVZ. Slides 136 were processed for immunohistochemistry and double immunofluorescence (described in 137 supplementary Methods and Materials), according to previously published procedures (22, 23, 26, 138 27) . 139
Cell counts 140
Cell counting was performed twice, blind to the clinical and neuropathological diagnosis, using a 141 Nikon Eclipse E800 microscope and the NIS elements software for bright field microscopy (version. were expressed as the number of immunopositive cells for each antibody/mm of length for all the 148 markers, in order to adjust for variances due to different lengths of the areas measured. 149
Statistical analysis 150
For all markers except doublecortin, negative binomial regression analysis was used to model the 151 difference in the number of immunopositive cells per mm length across groups defined by Braak 152 stage. Regression models were adjusted for age at death and for gender. Differences in cell counts 153 per mm between those with and without dementia at autopsy were assessed by negative binomial 154 regression adjusting for age at autopsy, gender and Braak stage. Negative binomial regression is a 155 count based regression model, and allows a number of events (immunopositive cells) to be modelled 156 in terms of covariates of interest (Braak stage and dementia diagnosis), as well as potentially 157 confounding covariates (age and sex), while also taking into account differences in an "exposure" 158 variable (length of tissue sample being examined). Negative binomial regression is a generalisation 159 of Poisson regression in that it allows for heterogeneity in the number of cells per mm across 160 individuals within a group. Poisson regression assumes an even distribution of immunopositive cells 161 across samples within groups and would lead to Type 1 errors since this assumption is highly 162 unlikely to be met. Negative binomial regression results in an estimate of "rate" (cells per mm) in 163 each group standardised to remove the effect of any differences in age and sex across groups and an 164 estimate of difference in terms of an "incident rate ratio" corresponding to the ratio of the rates across 165 groups, assuming all other covariates held constant. It should be noted that the rate estimate is very 166 similar to the raw count of cells/mm in each case, suggesting that the effect of any difference in age 167 and sex across groups in this analysis is minimal. 168
As a secondary albeit more conventional analysis, we conducted an analysis of variance (ANOVA) 169 across groups treating total cells per mm as a continuous outcome. This led to substantively similar 170 results, however it is likely that the outcome measure of cells per mm violates the assumptions of an 171 8 Ekonomou ANOVA (normally distribution with equal variances across groups) and so we prefer the negative 172 binomial regression as the primary analysis. 173
The numbers of cells positive for doublecortin were too small for meaningful multivariate analysis or 174 analysis using a count-based regression model, and so for each brain area the proportion of cases 175 with any doublecortin positive cells was compared across groups using Fisher"s exact tests. 176
An initial p value of p<0.05 was set for statistical significance, however owing to the large number 177 of hypotheses considered, we subsequently corrected for multiple testing using the method of 178
Benjamini and Hochberg (38) by setting a false discovery rate of q=0.05, leading to a revised critical 179 value of p<0.0016 for each individual hypothesis. Finally, Spearman"s correlation coefficients were 180 estimated to identify any association between the detected changes. For the data analysis, IBM SPSS 181 (version 19) and STATA (version 12.1) statistical software were used. 182 183
Results
184
Demographic data for the cohort are presented in Table 1 . Across the entire study cohort, the mean 185 age at death was 84.8 years (+/-8.6, range 71-103) and 50% of the participants were female (for 186 details see table 1 ). Statistical analysis showed that the post mortem delay was not related either to 187 Braak Stage and dementia diagnosis (p>0.05 for both) or to the cell counts of any of the markers 188 examined (data not shown). 189
The pattern of immmunoreactivity of the neural stem/progenitor cells and their progeny were 190 consistent with our previous descriptions (22, 23) . Nestin and doublecortin immunoreactivity was 191 observed in cellular somata and processes, although in the case of doublecortin, immunoreactivity in 192 the processes was rarely observed, possibly due to the post mortem delay, as described previously 193 (21) . As doublecortin is also expressed in astrocytes (39) , any doublecortin-positive cells with 194 astrocytic appearance (multiple processes) were excluded from counting. PCNA and HuC/D 195 immunoreactivity were detected in the cell nucleus. Figure 1 (A and B) shows the different cell There was a significantly lower number of GFAP-positive cells (identifying both neural stem cells 211 and astrocytes) among those with Braak stage III-IV (IRR=0.6; 95% CI=0.4-0.9) compared to those 212 with Braak stage 0-II, but a higher number among those in those in Braak stage V-VI (IRR=1.9; 95% 213 CI=1.3-2.8), and this difference across Braak groups remained statistically significant after 214 correction for multiple testing (p<0.0001, Figures 2B and 3 ). 215 Table 2 shows the difference in cell numbers per mm between those with and without dementia, and 216 the rate ratio standardised for age, gender and Braak stage. There is some evidence of an increase in 217 HuC/D-positive cell numbers in those with dementia (adjusted IRR=2.1; 95% CI=1.0-4.3; p=0.05). 218
As the number of doublecortin-positive cells was very low in the DG, a different statistical analysis 219 was performed, as described in Methods and Materials section. Table 3 shows the proportion of 220 cases with doublecortin-immunopositive cells in each brain area examined, with some evidence that 221 In order to examine potential correlations between the neurogenic and glial markers we performed 227
Spearman"s correlation (rho) analysis. There was a significant positive association between newly-228 generated neurons and the activated microglia (R=0.52, p=0.005), but negatively associated with the 229 changes of astrocytic cell numbers (R=-.396, p=0.045) in the DG (Table 4) . 230
231
SVZ and ependymal cell layer (anterior and temporal horn) 232
The neurogenic markers remained unchanged at the anterior (at the level of basal ganglia) and 233 temporal (at the level of hippocampus) horns of the SVZ and the ependymal cell layer adjacent to 234 those when analysed by Braak stage and by the presence of dementia (supplemental table S1 and  235   table 3 ). PCNA-HuC/D double and HuC/D single immunolabelled cells were not detected in these 236
areas. 237
The astrocytic and microglia markers also remained unchanged in the SVZ neurogenic niche and 238 neighbouring ependymal cell layer in Braak stages 0 to VI (supplemental table S1). 239
240
Discussion 241 A detailed analysis of endogenous neurogenesis in both neurogenic niches at various stages of tau 242 pathology in 28 people with and without AD was undertaken from a representative community 243 cohort of patients followed to autopsy (MRC CFA Study). This is a population-based representative 244 pilot study of endogenous neurogenesis in AD using human autopsy tissue, and focuses on the full 245 range of pathological disease severity, the cognitive status and both neurogenic niches from each 246 individual, compared to our previous studies (18, 19) . Furthermore, the study has the methodological 247 11 Ekonomou advantage of excluding patients with concurrent cerebrovascular pathology, Lewy body disease and 248 any other pathology that have been found to affect adult endogenous neurogenesis (22) (23) (24) (25) (26) (27) 40) , as 249 opposed to previous studies of endogenous neurogenesis in AD (20, 21) , including our previous 250 studies focussing on different patient cohorts (18, 19) where the percentage area of immunoreactivity 251 was measured rather than number of immunopositive cells. small vessel disease, as our previous studies have shown (22, 23, 26, 27, 40) . Markers of 264 neurogenesis did not vary between those with and without dementia after adjusting for Braak stage, 265 thus the reduced numbers of new neurons were specifically associated wih the severe Alzheimer 266
pathology. 267
Earlier studies examining endogenous neurogenesis in the course of AD have produced conflicting 268 results, possibly because of the predominant focus on more severe AD, variable concurrent vascular 269 changes and the limited focus on the later stages of neurogenesis, i.e. the newly-generated neurons. 270
The only other study to examine early neurons, as well as progenitors, reported a significant 271 12 Ekonomou reduction on their maturation as marked by the the decreased levels of MAP2a and MAP2b isoforms 272 in the DG of AD patients (20) , consistent with our current findings. 273
The present study exhibits some limitations, mainly due to methodology. As there are no reliable 274 and/or applicable markers to "visualise" and follow the fate of neural stem cells in the adult brain, it 275 is impossible to draw any conclusions about adult endogenous neurogenesis during the lifespan of 276 the participants in the study, so all our results represent adult neural stem cells and their progeny at a 277 single time point, that of autopsy. Optimistically, the development of new technologies will 278 facilitate this and clarify more the role of adult neurogenesis and its incolvement in cognitive decline 279 in ageing and AD. 280
As exclusion criteria were applied to the cases in reference to the presence of other 281 neurodegenerative diseases, our sample was modest (n=28), but it was a population-representative it 282 is pilot study of endogenous neurogenesis focussing upon "pure" AD in human autopsy tissue, 283
including individuals with different stages of AD pathology. 284
The use of antibodies as markers of endogenous neurogenesis on human autopsy tissue represents a 285 challenge, but we employed a validated battery of antibodies for the identification of progenitors and 286 newly-developed neurons at the various stages of neurogenesis in human autopsy tissue. Long post-287 mortem delay, quite common factor for obtaining human tissue, has been shown to alter but not 288 eliminate the immunostaining pattern for doublecortin, with similar overall levels of staining but 289 reduced staining within the soma. For example, Boekhoorn et al. (2006) have shown that post 290 mortem delay reduced immunoreactivity within the dendrites of doublecortin-positive neuroblasts 291 (21) . A similar pattern was seen for doublecortin in our study, but importanly the changes in the 292 overall pattern of staining by dementia stage were similar for other markers of neuroblasts/immature 293 neurons (HuC/D with PCNA). As it has been suggested that DCX can also be expressed in astrocytes 294 (39) and in dormant cells in non neurogenic areas (41, 42) , the use of HuC/D as an additional 295 marker for neuronal progenitors/early neurons is important and limits the possibility of over-296 13 Ekonomou interpreting results obtained from DCX immunohistochemistry. In addition, post-mortem delay was 297 not significantly correlated with the overall level of staining. Many hypotheses were explored and 298 when a correction was applied to ensure a false discovery rate of less than 0.05 only the changes 299 detected in the numbers of GFAP-immunopositive cells in the DG remained still statistically 300 significant across groups. 301
As there is an age-related decline in neurogenesis observed also in humans (43), our estimates have 302 also been adjusted for age, which further confirms the validity of our results. Physical activity and 303 certain pharmacological treatments such as SSRIs (for a review see 16, 17 and references therein) 304
can have an impact on neurogenesis in rodent models (44-51 and for a review 16, 17) . These were 305 not specifically examined in the current study, but it is unlikely that the magnitude of these effects 306 would be sufficient to confound the analysis. 307
The PCNA immunohistochemistry ( Figure 1B) also revealed a number of cells that are not co-308 expressing the neuronal fate marker HuC/D (green only cells in figure 1B ). Although these cells 309
were not counted for the study, we can speculate that they could represent astrocytic, microglial, or 310 endothelial cell proliferating progenitors or cells re-entering the cell cycle according to Yang et al. 311 (2003) (52), although that was not observed in the DG. 312
Our results still showed some evidence that although the early stages of endogenous neurogenesis 313 remained unchanged throughout the different Braak stages, severe AD pathology had a detrimental 314 effect on the numbers of newly-generated neurons in the DG of the affected individuals. In contrast, 315 endogenous neurogenesis at all stages and areas remained unchanged in individuals with dementia 316 compared to people without, suggesting that severe AD pathology impaired only the production of 317 new neurons. 318
We used Braak staging, a neurofibrillary tangle-based staging system, to describe the overall severity 319 of AD. Amyloid and tau pathology both increase with increasing disease severity, and many other 320 concurrent pathways related to a broad range of changes including inflammation and mitochondrial 321 14 Ekonomou function are activated. The specific mechanisms associated with the reduced production of new 322 neurones in people with severe AD are therefore difficult to unravel from the results of the current 323 study. Previous work has however suggested that tau transgenic mice (29, 53) do have reduced 324 neurogenesis, supporting the potential role of tau pathology as a contributor to this effect. 325
There was a significant positive correlation between the cell numbers of activated microglia and 326 those of the newly-generated neurons in the DG, suggesting that the reduction in activated microglia 327 in people with Braak stage V-VI tangle pathology may be a key driver for the decline in the newly-328 produced neurons in these individuals, along with the presence of tangles. Microglia have an 329 important role in adult neurogenesis in the healthy brain, as it has been demonstrated to control the 330 numbers of newly-produced neuron in the hippocampus through apoptosis (54) and can have both 331 pro-and anti-neurogenic effects, finely "tuning" adult neurogenesis (for a review see 55) . 332
For the first time, changes in GFAP-positive astrocytes have been examined at the various Braak 333 stages. Though we have no knowledge of the causal factors of these changes, one can hypothesize 334 that as astrocytes have a significant role in the support and protection of neurons in the healthy brain, 335 the decrease identified at Braak stage III-IV, below the levels seen in individuals with Braak stage 0-336 II, could be another contributing factor to the disease progression and pathology. The two-fold 337 increase above the levels observed in the healthy brain in astrocytes numbers in the Braak stage V-VI 338 could have a detrimental effect on the diseased brain, as it has been described for certain 339 neurodegenerative diseases, including dementia (for a review see 56) . A separate study further 340 investigating this hypothesis could clarify that observation and the underlying mechanism(s). 341
Our study examined the fate of neuronal progenitors and their progeny at the DG and the anterior 342 and temporal horn SVZ and adjacent ependymal layers in various stages of AD, without any effect 343 from concurrent cerebrovascular or other neuropathology, and showed that specific and significant 344 reductions in newly-generated neurons were detected only in the DG of those with severe AD 345 pathology, and were associated to the microglial load of the area. Previous studies (57-59) 346 15 Ekonomou identifying that abnormal endogenous neurogenesis relates to age-related learning impairment have 347 indicated that the manipulation of endogenous neurogenesis may be a potential treatment target in 348 people with AD. As a cross-sectional autopsy study, our results have to be interpreted cautiously, 349 but our findings do support the concept for an enhancement of aspects of endogenous neurogenesis, 350 as a possible treatment target in AD. Statistical analysis was performed using a two-tailed Spearman"s rho correlation analysis. R: correlation coefficient. Statistical significance: *: p < 0.05 and **: p < 0.01. 
Figure legends
Stage-Specific Changes in Neurogenic and Glial Markers in Alzheimer's Disease
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Immunohistochemistry
After deparaffinization, rehydration and microwave pressure cooking antigen retrieval using 10 mM citrate buffer, pH 6, slides were processed for immunohistochemistry using DAB Sudan Black B (SIGMA, UK) in 70% methanol solution, as previously described (4) . Adjacent sections were incubated in the absence of the primary or secondary antibodies in order to determine non-specific antibody binding, and they were devoid of immunoreactivity ( Figure S2B and S2C). Cells/mm and incident rate ratios (IRR) (compared to the group with Braak stage 0-2 as a reference) are estimated by negative binomial regression. Adjusted cells per mm are standardized to the sample age and gender and numbers in parentheses represent standard error. None of the differences across groups are statistically significant. GFAP, glial fibrillary acidic protein; SVZ BG, subventricular zone at the level of basal ganglia (anterior horn); EP BG, ependymal cell layer at the level of basal ganglia, adjacent to SVZ BG.
